21:35 , Aug 3, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant Pharmaceuticals International Inc. CompanyDatePre/post mkt2Q18 EPS est2Q17 EPSExpected chgBausch Health Companies Inc. (TSX:BHC; NYSE:BHC) (A)8/7Pre$0.80$1.03-22%Jazz Pharmaceuticals plc...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
00:06 , May 5, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 11 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) 12-month EPS; Source: Yahoo! Finance, Financial Times, company websites CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgMyriad Genetics...
19:08 , Apr 20, 2018 |  BC Week In Review  |  Company News

Advent to acquire Sanofi's EU generics business

VC firm Advent International Corp. (Boston, Mass.) said it will acquire from Sanofi (Euronext:SAN; NYSE:SNY) the pharma's European generics business, Zentiva Group A/S, for €1.9 billion ($2.3 billion). Last year, Sanofi indicated it was looking to...
19:24 , Apr 17, 2018 |  BC Extra  |  Company News

Advent to acquire Sanofi's European generics unit for €1.9B

VC firm Advent International Corp. (Boston, Mass.) said it will acquire from Sanofi (Euronext:SAN; NYSE:SNY) the pharma's European generics business, Zentiva Group A/S, for €1.9 billion ($2.3 billion). Last year, Sanofi indicated it was looking...
22:49 , Apr 3, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, Dermavant, Assembly

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) said President and CEO Timothy Miller will transition to president and CSO. He is succeeded as CEO by Carsten Thiel, who was EVP and chief commercial officer at...
20:50 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Arca reports Phase IIb data for Gencaro in heart failure patients

Arca biopharma Inc. (NASDAQ:ABIO) reported top-line data from the Phase IIb GENETIC-AF trial in 267 heart failure patients with reduced left ventricular ejection fraction (LVEF) showing that Gencaro bucindolol hydrochloride led to a "similar treatment...
00:12 , Feb 24, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least four profitable biotechs and pharmas are slated to report earnings this week. CompanyDatePre/post mkt4Q17 EPS est4Q16 EPSExpected chgEndo International plc (NASDAQ:ENDP)2/27Pre$0.61$1.77-66%Jazz Pharmaceuticals plc (NASDAQ:JAZZ)2/27Post$3.01$2.7111%Bayer AG (Xetra:BAYN)2/28Pre€ 1.16€ 1.19-3%Valeant Pharmaceuticals International Inc. (NYSE:VRX;...
22:11 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample, cell culture and mouse studies suggest inhibiting IRF3 could help treat gastric cancer. In patient samples, high levels of IRF3 tumor RNA and protein correlated with tumor size and poor survival....
20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...